THE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PRO-ACTIVE PATIENT TOOLKIT



Resource Guide

Engage in Your DLBCL Care

- Educate yourself about DLBCL. Ask your team for recommendations for credible sources of information.
- Consider a second opinion or a consult with a DLBCL specialist immediately following your diagnosis.
- Make a list of questions prior to your appointments and bring a friend or family member along to visits.
- Understand and articulate the goals of your DLBCL treatment plan and ask if a clinical trial may be right for you.
- Learn about your options and discuss the pros and cons of each approach with your doctor.
- Speak up and share your questions and concerns. YOU are your own best advocate.

DLBCL Treatment Considerations Include:

- Age and overall health.
- The location and stage of the DLBCL at the time of treatment.
- Lab test results, including biomarker test results.
- The potential side effects of each option.

DLBCL Resources

Cancer Support Community: cancersupportcommunity.org

The Leukemia & Lymphoma Society (LLS): LLS.org
Lymphoma Research Foundation: lymphoma.org
Clinical Trials: clinicaltrials.gov

Glossary Terms

B Cells: Part of a person's immune system that develops from stem cells in the bone marrow.

Bispecific Antibodies: Antibodies that bind to two different antigens at the same time. These antibodies are being studied in the treatment of cancer.

CAR (Chimeric Antigen Receptor) T-Cell Therapy: Treatment in which the T cells (a type of immune system cell) of a patient are laboratory-altered to attack cancer cells in the body.

Double Hit Lymphoma (DHL): An aggressive type of B-cell non-Hodgkin lymphoma (NHL) characterized by re-arrangements of two genes, the MYC gene and either BCL-2 or BCL-6 gene.

Immunotherapy: Type of therapy that harnesses one's own immune system to help the body fight cancer, infection, and other diseases.

Relapsed Disease: The disease or symptoms have returned following a period of remission.

Targeted Therapy: A type of personalized medicine that works by blocking specific mutations and by preventing cancer cells from growing and dividing, without affecting normal cells.

The DLBCL Toolkit is brought to you by the Patient Empowerment Network. Funding is provided by an unrestricted educational grant from Pharmacyclics, an AbbVie Company, and Bristol Myers Squibb.



question@powerfulpatients.org

www.powerfulpatients.org



@power4patients